Non-medical and illicit use of psychoactive drugs

1. Front Matter

   Pages i-xiv

   PDF

2. Preclinical Effects of Antipsychotic Drugs

   • Jenny Paola Berrío Sánchez, Bart A. Ellenbroek

   Pages 1-16

3. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (‘Ecstasy’) Substance Use Disorder

   • Susan Schenk, Dane Aronsen

   Pages 17-32

4. The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research

   • Sharon L. Walsh, Shanna Babalonis

   Pages 33-58

5. Over-the-Counter Codeine—from Therapeutic Use to Dependence, and the Grey Areas in Between

   • Suzanne Nielsen, Marie Claire Van Hout

   Pages 59-75

6. Injection of Pharmaceuticals Designed for Oral Use: Harms Experienced and Effective Harm Reduction Through Filtration

   • Stuart McLean, Rahul Patel, Raimondo Bruno

   Pages 77-98

7. Misuse of Methylphenidate

   • David B. Clemow

   Pages 99-124

8. Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics

   • Mark E. Montebello, Jonathan Brett

   Pages 125-139

9. Benzodiazepines

   • Suzanne Nielsen

   Pages 141-159

10. Recent Trends in Alcohol and Other Drug Use Among Police Detainees in New Zealand, 2010–2015

    • Chris Wilkins, Jitesh Prasad, Karl Parker, Marta Rychert, Helen Moewaka Barnes

    Pages 161-172

11. The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the USA

    • Priscillia E. Hunt, Jeremy Miles

    Pages 173-198

This volume is devoted to descriptions of non medical as well as medical uses for some drugs that have typically, or not so typically, been associated with drug abuse. One major objective of this book is to identify costs and benefits of drug abuse. The book highlights drugs including 3,4 methylenedioxymethamphetamine (MDMA), cannabinoids, opioids and methylphenidate  because of their well-documented potential for abuse and provides new and emerging evidence of their potential to treat some chronic disease states alongside the potential consequences of exposure.  

• Antipsychotics
• Benzodiazepines
• Cannabínoids
• Illicit and licit use
• Opioids
• Psychostimulants

• National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

  Suzanne Nielsen

• University of Tasmania School of Psychology, Launceston, Australia

  Raimondo Bruno

• Victoria University of Wellington School of Psychology, Wellington, New Zealand

  Susan Schenk

Policies and ethics